| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Pharmacology and 2 Howard Hughes Medical Institute and Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Valproic acid (VPA), a well-established therapy for seizures and bipolar disorder, has recently been shown to inhibit histone deacetylases (HDACs). Similar to more widely studied HDAC inhibitors, VPA can cause growth arrest and induce differentiation of transformed cells in culture. Whether this effect of VPA is through inhibition of HDACs or modulation of another target of VPA has not been tested. We have used a series of VPA analogs to establish a pharmacological profile for HDAC inhibition. We find that VPA and its analogs inhibit multiple HDACs from class I and class II (but not HDAC6 or HDAC10) with a characteristic order of potency in vitro. These analogs also induce hyperacetylation of core histones H3 and H4 in intact cells with an order of potency that parallels in vitro inhibition. VPA and VPA analogs induce differentiation in hematopoietic cell lines in a p21-dependent manner, and the order of potency for induction of differentiation parallels the potencies for inhibition in vitro, as well as for acetylation of histones associated with the p21 promoter, supporting the argument that differentiation caused by VPA is mediated through inhibition of HDACs. These findings provide additional evidence that VPA, a well-tolerated, orally administered drug with extensive clinical experience, may serve as an effective chemotherapeutic agent through targeting of HDACs.
This article has been cited by other articles:
|
|
 |
|
  O. H. Kramer, S. Muller, M. Buchwald, S. Reichardt, and T. Heinzel Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RAR{alpha} FASEB J, May 1, 2008; 22(5): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schuetz, J. Min, A. Allali-Hassani, M. Schapira, M. Shuen, P. Loppnau, R. Mazitschek, N. P. Kwiatkowski, T. A. Lewis, R. L. Maglathin, et al. Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity J. Biol. Chem., April 25, 2008; 283(17): 11355 - 11363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bicaku, D. C. Marchion, M. L. Schmitt, and P. N. Munster Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling Cancer Res., March 1, 2008; 68(5): 1513 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Cucciolla, A. Borriello, M. Criscuolo, A. A. Sinisi, D. Bencivenga, A. Tramontano, A. C. Scudieri, A. Oliva, V. Zappia, and F. D. Ragione Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor Carcinogenesis, March 1, 2008; 29(3): 560 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La, Y. Yang, S. K. Karnik, A. C. Silva, R. W. Schnepp, S. K. Kim, and X. Hua Menin-mediated Caspase 8 Expression in Suppressing Multiple Endocrine Neoplasia Type 1 J. Biol. Chem., October 26, 2007; 282(43): 31332 - 31340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G Catalano, R. Poli, M. Pugliese, N. Fortunati, and G. Boccuzzi Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines Endocr. Relat. Cancer, September 1, 2007; 14(3): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Y. Greenblatt, A. M. Vaccaro, R. Jaskula-Sztul, L. Ning, M. Haymart, M. Kunnimalaiyaan, and H. Chen Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells Oncologist, August 1, 2007; 12(8): 942 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim, M. Rowe, M. Ren, J.-S. Hong, P.-S. Chen, and D.-M. Chuang Histone Deacetylase Inhibitors Exhibit Anti-Inflammatory and Neuroprotective Effects in a Rat Permanent Ischemic Model of Stroke: Multiple Mechanisms of Action J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 892 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, R. B. Klisovic, T. Vukosavljevic, J. Yu, P. Paschka, L. Huynh, J. Pang, P. Neviani, Z. Liu, W. Blum, et al. Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 953 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, A. Muller-Taubenberger, K. E. Adley, N. Pawolleck, V. W. Y. Lee, C. Wiedemann, T. S. Sihra, M. Maniak, T. Jin, and R. S. B. Williams Attenuation of Phospholipid Signaling Provides a Novel Mechanism for the Action of Valproic Acid Eukaryot. Cell, June 1, 2007; 6(6): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jessberger, K. Nakashima, G. D. Clemenson Jr, E. Mejia, E. Mathews, K. Ure, S. Ogawa, C. M. Sinton, F. H. Gage, and J. Hsieh Epigenetic Modulation of Seizure-Induced Neurogenesis and Cognitive Decline J. Neurosci., May 30, 2007; 27(22): 5967 - 5975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Munster, D. Marchion, E. Bicaku, M. Schmitt, J. H. Lee, R. DeConti, G. Simon, M. Fishman, S. Minton, C. Garrett, et al. Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study J. Clin. Oncol., May 20, 2007; 25(15): 1979 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Miyatake, T. Kuno, A. Kita, K. Katsura, K. Takegawa, S. Uno, T. Nabata, and R. Sugiura Valproic Acid Affects Membrane Trafficking and Cell-Wall Integrity in Fission Yeast Genetics, April 1, 2007; 175(4): 1695 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Huang and B. Guo Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res., September 15, 2006; 66(18): 9245 - 9251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Z. Qian, S. K. Kachhap, S. J. Collis, H. M.W. Verheul, M. A. Carducci, P. Atadja, and R. Pili Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha} Cancer Res., September 1, 2006; 66(17): 8814 - 8821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kawai and I. J. Arinze Valproic Acid-Induced Gene Expression through Production of Reactive Oxygen Species. Cancer Res., July 1, 2006; 66(13): 6563 - 6569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Wilson, D.-S. Byun, N. Popova, L. B. Murray, K. L'Italien, Y. Sowa, D. Arango, A. Velcich, L. H. Augenlicht, and J. M. Mariadason Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer J. Biol. Chem., May 12, 2006; 281(19): 13548 - 13558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Eikel, K. Hoffmann, K. Zoll, A. Lampen, and H. Nau S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES AND AMIDES Drug Metab. Dispos., April 1, 2006; 34(4): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H. Kramer, D. Baus, S. K. Knauer, S. Stein, E. Jager, R. H. Stauber, M. Grez, E. Pfitzner, and T. Heinzel Acetylation of Stat1 modulates NF-{kappa}B activity. Genes & Dev., February 15, 2006; 20(4): 473 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Qiao, J. Schaack, and J. Shao Suppression of Adiponectin Gene Expression by Histone Deacetylase Inhibitor Valproic Acid Endocrinology, February 1, 2006; 147(2): 865 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michaelis, T. Suhan, A. Reinisch, A. Reisenauer, C. Fleckenstein, D. Eikel, H. Gumbel, H. W. Doerr, H. Nau, and J. Cinatl Jr Increased Replication of Human Cytomegalovirus in Retinal Pigment Epithelial Cells by Valproic Acid Depends on Histone Deacetylase Inhibition Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3451 - 3457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akbarian, M. G. Ruehl, E. Bliven, L. A. Luiz, A. C. Peranelli, S. P. Baker, R. C. Roberts, W. E. Bunney Jr, R. C. Conley, E. G. Jones, et al. Chromatin Alterations Associated With Down-regulated Metabolic Gene Expression in the Prefrontal Cortex of Subjects With Schizophrenia Arch Gen Psychiatry, August 1, 2005; 62(8): 829 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shen, J. Li, and P. Casaccia-Bonnefil Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain J. Cell Biol., May 23, 2005; 169(4): 577 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Klass, L. T. Krug, V. P. Pozharskaya, and M. K. Offermann The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production Blood, May 15, 2005; 105(10): 4028 - 4034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Marchion, E. Bicaku, A. I. Daud, D. M. Sullivan, and P. N. Munster Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins Cancer Res., May 1, 2005; 65(9): 3815 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Kernochan, M. L. Russo, N. S. Woodling, T. N. Huynh, A. M. Avila, K. H. Fischbeck, and C. J. Sumner The role of histone acetylation in SMN gene expression Hum. Mol. Genet., May 1, 2005; 14(9): 1171 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Eickholt, G. J. Towers, W. J. Ryves, D. Eikel, K. Adley, L. M. J. Ylinen, N. H. Chadborn, A. J. Harwood, H. Nau, and R. S. B. Williams Effects of Valproic Acid Derivatives on Inositol Trisphosphate Depletion, Teratogenicity, Glycogen Synthase Kinase-3{beta} Inhibition, and Viral Replication: A Screening Approach for New Bipolar Disorder Drugs Derived from the Valproic Acid Core Structure Mol. Pharmacol., May 1, 2005; 67(5): 1426 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Mongan and L. J. Gudas Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR{beta}2 in breast cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 477 - 486. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
